348 related articles for article (PubMed ID: 28623912)
1. Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.
Rastgoo N; Abdi J; Hou J; Chang H
J Hematol Oncol; 2017 Jun; 10(1):121. PubMed ID: 28623912
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
Dupéré-Richer D; Licht JD
Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
[TBL] [Abstract][Full Text] [Related]
3. [The epigenetic alteration and the effect of HDAC inhibitors in multiple myeloma].
Terui Y
Nihon Rinsho; 2015 Jan; 73(1):124-9. PubMed ID: 25626317
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance in multiple myeloma.
Robak P; Drozdz I; Szemraj J; Robak T
Cancer Treat Rev; 2018 Nov; 70():199-208. PubMed ID: 30245231
[TBL] [Abstract][Full Text] [Related]
5. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.
Amodio N; D'Aquila P; Passarino G; Tassone P; Bellizzi D
Expert Opin Ther Targets; 2017 Jan; 21(1):91-101. PubMed ID: 27892767
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
Amodio N; Stamato MA; Gullà AM; Morelli E; Romeo E; Raimondi L; Pitari MR; Ferrandino I; Misso G; Caraglia M; Perrotta I; Neri A; Fulciniti M; Rolfo C; Anderson KC; Munshi NC; Tagliaferri P; Tassone P
Mol Cancer Ther; 2016 Jun; 15(6):1364-75. PubMed ID: 27196750
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M
Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
Furukawa Y; Kikuchi J
Int J Hematol; 2016 Sep; 104(3):281-92. PubMed ID: 27411688
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic targeting in pancreatic cancer.
van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
[TBL] [Abstract][Full Text] [Related]
11. Cancer epigenetics: Moving forward.
Nebbioso A; Tambaro FP; Dell'Aversana C; Altucci L
PLoS Genet; 2018 Jun; 14(6):e1007362. PubMed ID: 29879107
[TBL] [Abstract][Full Text] [Related]
12. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance.
Puła A; Robak P; Robak T
Curr Med Chem; 2021 Oct; 28(33):6753-6772. PubMed ID: 33949926
[TBL] [Abstract][Full Text] [Related]
14. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H
BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931
[TBL] [Abstract][Full Text] [Related]
15. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
16. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
Valdespino-Gómez VM; Valdespino-Castillo VE
Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
[TBL] [Abstract][Full Text] [Related]
17. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease.
Garcia-Gomez A; Li T; de la Calle-Fabregat C; Rodríguez-Ubreva J; Ciudad L; Català-Moll F; Godoy-Tena G; Martín-Sánchez M; San-Segundo L; Muntión S; Morales X; Ortiz-de-Solórzano C; Oyarzabal J; San José-Enériz E; Esteller M; Agirre X; Prosper F; Garayoa M; Ballestar E
Nat Commun; 2021 Jan; 12(1):421. PubMed ID: 33462210
[TBL] [Abstract][Full Text] [Related]
18. Targeting Chromatin Remodeling for Cancer Therapy.
Kaur J; Daoud A; Eblen ST
Curr Mol Pharmacol; 2019; 12(3):215-229. PubMed ID: 30767757
[TBL] [Abstract][Full Text] [Related]
19. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y
Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772
[TBL] [Abstract][Full Text] [Related]
20. Role of micro-RNAs in drug resistance of multiple myeloma.
Abdi J; Jian H; Chang H
Oncotarget; 2016 Sep; 7(37):60723-60735. PubMed ID: 27494872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]